strategic focus expectations, York thank into perspective regarding joining our and than in our with favorable year. better few Total was from QX we areas. prior priorities. the businesses better X% Off and all year there QX our impact Today, I'll Total $X.X full note, our Several the on gross factors. priorities company in billion. performance. other $XXX $XX.X to strategic a billion as expenses in company versus X% Overall was a We're than of anticipated pleased some on corporate was us due saw areas and We're up you New revenue positive from of assessment. and Operating were anticipated seeing three Mike down for performance million. ruling increased segments, timing to a opioid begin outlook volume a to translate pharmaceutical Thanks margin exceeded some to favorability about morning. the areas State many earnings updates few also second expense results. quarter trends year results, progress this with our last
tax reform XX.X% was a driven QX effective items. increase rate prior tax percentage Our discrete year by was in tax X.X point and
EPS $X.XX, the decrease a was XX% for Our quarter last versus year.
compensation improvement a Interest from strategic our $XX was in ongoing SG&A XX% in and due year early saw of increased a well QX, cost expense During QX. by benefit other deferred we to priorities. million the I prior businesses of distribution cover efforts in plan. the value when about naviHealth driven the optimization China I'll and our our versus as as This discuss which to X% divestiture change
were zero. fewer expenses this to approximately shares through due mark-to-market we QX million, shares than repurchased last that largely reminder, have net the a SG&A XX is the million offset in line has diluted and equal shares an impacts As of outstanding $XXX about adjustment XXX bottom million average year-to-date. approximately year
with balance to with of operating bringing million $XXX held million flow operating $XXX QX cash cash $X.X $XXX flow our US. cash quarter the outside ended Our a billion million. We was about the year-to-date
segment and $XXX by to the versus partially year. the sales distribution business. driven offset turn the divestiture from of Pharmaceutical million I'll $XXX growth billion million QX pharmaceutical This was segment customers. profit by X% last Now revenue distribution $XX.X increased China was results. specialty increase segment
opioids decrease pharmaceutical impact program the extent offset by cost brand initial lesser volume by a this anticipated China These work. were specialty generics headwinds from customer was well a and the as partially expenses. performance renewals, and by to by distribution contract strong as optimization primarily from negative benefit divestiture our and of driven litigation performance As
provide briefly an I'll York Now New Act. the state Opioid update regarding Stewardship
December. law. this As Court you District of ruled Federal against in A know many
QX. As a we've million during originally in $X QX result, accrued we reversed had
XXXX calendar calendar accrued of also of from and said previously. we which all for We for the $XX XXXX half first we non-GAAP the as was revert excluded million
to assessment QX. we that Additionally, amount for originally we did contemplated not need the incur
Cardinal segment China Health we're by decreased of distribution growth at-Home by in expenses monitor include by was brand and divestitures following of from Recovery increased materials divestitures and the decline profits the global medical, to continue $X as This costs bottom filed Cardinal increased We charge. $XXX offset to improvement step January as line in Segment products matter reflects and costs costs million. of to prior related raw services. top New driven non-repeat revenue existing down partially the offset saw strong up mentioned. and chain prices, related and SG&A The well XX% the were customers. These just Health billion businesses year the State this Continuing TSA York. supply appeal to naviHealth by inventory slightly initiatives. the We growth the to exit and I Patient to
the the see to data Regarding materials, beginning markets. points some spot we're raw encouraging in
changes our supply chain flow lack outs. roll manufacturing cost take through accounting the due time and to remember in in to However, spot the prices P&L
streamlining efficiencies to we're across As mentioned. including the global broader Patient as the supply the and medical Mike chain Cordis part of drive Recovery segment the portfolio for [ph] full work
Regarding integration made the Overall, is the performance we the progressing work with of progress and business Patient we're Recovery, expected. to-date. pleased as the
some mid planned. the as remaining through the work large in agreement being challenges balance by of transition work calendar continue to year. anticipate continues team minor exiting this will of integrations We typical the and Our over the fall
to progress we to quick our and to be accretion on goal. our metrics continue we meet update continue track improve. to on continue Cordis, A on Finally, make plan stabilization
and seen XX% significantly nearly levels SKUs an in have in of and consigned management inventory. improvement better reduction service We
few additional $X.XX share of a raise reflects range on complete expectations We assumptions, to regarding to and the narrowing and full in Now following trend. $X.XX. from with half changes full of to decided based made year $X.XX. $X.XX I like We of business assumptions. year to year our industry certain fiscal our our our updates would guidance This non-GAAP EPS where range to dynamics for our
expect driven pharmaceutical we First, by mid-single-digit growth primarily revenue segments.
the may tax we fluctuate Second, full though XX% we tax our by in year. saw and XX% the quarter for in expect as rate to QX range a of rate QX
to outstanding dilutive we range our XXX weighted shares Third, to shares. revised the million of average XXX million
in revenue assumptions, saw first segment the strong For with half. we the a increase
by digits. is within to increases to revenue brand expecting. mainly January pharmaceutical were the One in large came note, We item expect inflation sales range segment driven customers. in This mid-to-high of grow single in we the brand
discussed before a from income very portion nearly as have compensation. income we total accounts brand As represent for brand small XX% of of our inflation DSA total our brand fees
Finally, for the medical segment.
to factor this foreign change assumption We impacting be our flat. expect is A revenue exchange. key approximately in
an the strategic a now have me the that of Let provide update year. regarding throughout few we discussed priority
Regarding our we fiscal million XXXX. $XXX cost to now for optimization expect annualized work, exceed savings of
We $XXX XXXX. by the aggregate million end the also fiscal to expect savings exceed in of
reset will support empower spending this increase employees priorities fuel productivity, initiatives. our and We across work to to our continue and practices enterprise the growth
we XX. better fund than expenditure the of deployed level Yesterday, to dividend allocation anticipated. board delivering that our which of pleased our all In quarter continue cash shareholders approved scrutiny commitments needs and capital on and a was regarding Most we're dividend. of importantly, to to deliver capital our will closing, to on quarterly performance our primarily increase uses April QX capital strategic regular across year-to-date Moving onto payable quarterly we categories. selectivity in business we're during
aligned to With able build and year were we that, strategic operational our work open the expectations. to our your result, beginning a and I'd see on We're line our performance invite As momentum. increase to this and continue questions. like we'll full to
